The companies enter into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, following co-operation for TENELIA® Tablets, a selective DPP-4 inhibitor, and CANAGLU® Tablets, an SGLT2 inhibitor
OSAKA and TOKYO, Japan I March 29, 2017 I Mitsubishi Tanabe Pharma Corporation (hereafter Mitsubishi Tanabe Pharma; Head Office: Chuo-ku, Osaka; President & Representative Director, CEO: Masayuki Mitsuka) and Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo; Head Office: Chuo-ku, Tokyo; Representative Director, President & CEO: George Nakayama) announced today that both companies have agreed to expand their strategic alliance in the field of diabetes and have entered into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, and for which an application has already been filed in Japan.
Based on this agreement, Daiichi Sankyo will market MT-2412 after the receipt of manufacturing and marketing approval by Mitsubishi Tanabe Pharma, while both companies will co-promote it.
MT-2412 is a combination drug consisting of TENELIA® Tablets, a selective DPP-4 inhibitor (generic name: teneligliptin), and CANAGLU® Tablets,an SGLT2 inhibitor (generic name: canagliflozin). Both TENELIA® and CANAGLU® have been prescribed to many patients in Japan and have been increasingly used, not only respectively as single agents, but also in drug combinations. Both companies expect that combining the two drugs into a single agent will enhance convenience and improve medication adherence for patients already on combination regimens, as well as for potential patients for whom combination regimens are being considered.
In March 2012, Mitsubishi Tanabe Pharma and Daiichi Sankyo entered a marketing alliance agreement for TENELIA® and CANAGLU®. Since then, the marketing of TENELIA® has been conducted by Daiichi Sankyo, whereas the marketing of CANAGLU® has been carried out by Mitsubishi Tanabe Pharma. Both companies have jointly engaged in co-promotion of the two products.
Mitsubishi Tanabe Pharma and Daiichi Sankyo aim to contribute to the treatment of each patient by providing novel options for type 2 diabetes mellitus, as well as by engaging in prompt and proper information provision activities through the alliance between both companies.
SOURCE: Daiichi Dankyo
Post Views: 32
The companies enter into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, following co-operation for TENELIA® Tablets, a selective DPP-4 inhibitor, and CANAGLU® Tablets, an SGLT2 inhibitor
OSAKA and TOKYO, Japan I March 29, 2017 I Mitsubishi Tanabe Pharma Corporation (hereafter Mitsubishi Tanabe Pharma; Head Office: Chuo-ku, Osaka; President & Representative Director, CEO: Masayuki Mitsuka) and Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo; Head Office: Chuo-ku, Tokyo; Representative Director, President & CEO: George Nakayama) announced today that both companies have agreed to expand their strategic alliance in the field of diabetes and have entered into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, and for which an application has already been filed in Japan.
Based on this agreement, Daiichi Sankyo will market MT-2412 after the receipt of manufacturing and marketing approval by Mitsubishi Tanabe Pharma, while both companies will co-promote it.
MT-2412 is a combination drug consisting of TENELIA® Tablets, a selective DPP-4 inhibitor (generic name: teneligliptin), and CANAGLU® Tablets,an SGLT2 inhibitor (generic name: canagliflozin). Both TENELIA® and CANAGLU® have been prescribed to many patients in Japan and have been increasingly used, not only respectively as single agents, but also in drug combinations. Both companies expect that combining the two drugs into a single agent will enhance convenience and improve medication adherence for patients already on combination regimens, as well as for potential patients for whom combination regimens are being considered.
In March 2012, Mitsubishi Tanabe Pharma and Daiichi Sankyo entered a marketing alliance agreement for TENELIA® and CANAGLU®. Since then, the marketing of TENELIA® has been conducted by Daiichi Sankyo, whereas the marketing of CANAGLU® has been carried out by Mitsubishi Tanabe Pharma. Both companies have jointly engaged in co-promotion of the two products.
Mitsubishi Tanabe Pharma and Daiichi Sankyo aim to contribute to the treatment of each patient by providing novel options for type 2 diabetes mellitus, as well as by engaging in prompt and proper information provision activities through the alliance between both companies.
SOURCE: Daiichi Dankyo
Post Views: 32
